ArticleBMC geriatrics2025
The relationship between stroke-related sarcopenia and 3-month neurological outcome in stroke patients: a prospective cohort study.
Article in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of Sarcopenia With Global, Motor, Cognitive, and Swallowing Function Prognosis in Stroke Patients: A Systematic Review and Meta-Analysis.Brain and behavior · 2026Pooled it
- Sarcopenic obesity defined by the Asia-Oceania consensus and its association with activities of daily living in post-stroke patients: a retrospective cohort study.European geriatric medicine · 2026Article
- Post-stroke sarcopenia as a neuromuscular disorder: a mini review of neural mechanisms and clinical implications.Frontiers in neurology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundSarcopenia was initially defined as an age-related decline in muscle mass and function. As sarcopenia has been observed at any age and secondary to many diseases, extending the classical meaning of sarcopenia beyond the age-related phenomenon to the 'disease-related' sarcopenia has been debated recently. Stroke-related sarcopenia occurs secondary to the brain injury and is age-independent, potentially worsening patients' neurological outcomes. We aimed to explore the relationship between stroke-related sarcopenia and 3-month neurological outcome in stroke patients, as well as to evaluate the predictive value of the two main indicators of stroke-related sarcopenia-muscle mass and muscle strength-for adverse neurological outcomes.
methodsA single-centre prospective cohort study of 228 individuals with ischaemic stroke who were admitted for routine rehabilitation treatment, followed up for neurological outcome for 3 months following the onset of the stroke. The muscle mass was expressed by the ratio of appendicular skeletal muscle mass (ASM) to height (Ht) (ASM/Ht
resultsThe prevalence of sarcopenia was 28.9% in all included patients. Compared with the good outcome group, the poor outcome group showed a significantly lower level of ASM/Ht
conclusionsStroke-related sarcopenia is closely related to worse neurological function at the convalescence stage. Higher ASM/Ht
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.